|View printer-friendly version|
Spring Bank Pharmaceuticals HCV drug SB 9200 has demonstrated pan genotypic antiviral activity against all HCV genotypes in the hybrid fusion assay
Milford, November 11, 2013. Spring Bank Pharmaceuticals, Inc. of Milford, MA today announced that Dr. Graham Foster from Queen Mary University of London, presented a Poster entitled “Pan-genotypic anti-HCV activity of SB9200 assessed in the ‘capture-fusion’ replication assay’ at the recently concluded conference of the American Association for the Study of Liver Diseases (AASLD) at Washington DC.
Dr. Foster, a clinician and leader in the field of Hepatitis research has developed a novel model of HCV replication that is highly predictive of clinical outcome of potential antivirals. The capture fusion assay was used to assess the genotypic range of SB 9200, a clinical stage, host-targeted agent developed by Spring Bank for the treatment of Hepatitis C and Hepatitis B. In the capture-fusion assay, SB 9200 demonstrated potent antiviral activity against all the tested HCV genotypes 1a, 1b, 2, 3, 4 and 6. These results support the potential use of SB 9200 as a pan-genotypic, host-targeting anti-HCV agent that can be used with different classes of direct-acting antivirals in combination therapy. The results also support the novel mechanism of action of SB 9200 involving the activation of cellular viral sensors RIG-I and NOD2 for inducing antiviral state in cells.
Contact: 508-473-5993 Extension 105